Abraxis BioScience Receives FDA Approval for Caffeine Citrate Injection USP, 20 mg/mL

  
    
  
  
    
      Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global 
      biopharmaceutical company, today announced that its hospital-based 
      products business, Abraxis Pharmaceutical Products (APP), has received 
      approval from the U.S. Food and Drug Administration (FDA) for its 
      Abbreviated New Drug Application (ANDA) for Caffeine Citrate injection, 
      USP, 20 mg/mL, the generic equivalent of Cafcit® 
      Injection manufactured by Mead Johnson and Company. According to IMS 
      data, annual sales in 2006 of this product across all distributors and 
      dosage forms were approximately $16 million. APP will package this 
      product in 60 mg/3mL single-use vials and expects to commence marketing 
      of this product immediately.
    
    
      Caffeine Citrate Injection is indicated for the short term treatment of 
      apnea of prematurity (AOP) in infants between 28 and